BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Breast cancer AND MAP2K4, MEK4, 6416, P45985, ENSG00000065559, SERK1, JNKK1, MKK4, PRKMK4, MAPKK4, JNKK, SEK1 AND Treatment
13 results:

  • 1. mkk4 Inhibitors-Recent Development Status and Therapeutic Potential.
    Katzengruber L; Sander P; Laufer S
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108658
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Selinexor demonstrates anti-tumor efficacy in paired patient-derived xenograft models and hydrogel-embedded histoculture drug sensitivity test of penile cancer.
    He Y; Mei J; Hao H; Liu F; Yi Y; Hu C; Zou F; Lu X
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):6931-6941. PubMed ID: 36840755
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Mammary mucinous cystadenocarcinoma with long-term follow-up: molecular information and literature review.
    Lei T; Shi YQ; Chen TB
    Diagn Pathol; 2023 Feb; 18(1):13. PubMed ID: 36737820
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. A novel methuosis inducer DZ-514 possesses antitumor activity via activation of ROS-mkk4-p38 axis in triple negative breast cancer.
    Wang L; Mi D; Hu J; Liu W; Zhang Y; Wang C; Chen Y; Chen C
    Cancer Lett; 2023 Feb; 555():216049. PubMed ID: 36608865
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence.
    Conforti F; Pala L; Pagan E; Viale G; Bagnardi V; Peruzzotti G; De Pas T; Bianco N; Graffeo R; Rocco EG; Vingiani A; Gelber RD; Coates AS; Colleoni M; Goldhirsch A
    Breast Cancer Res; 2019 Dec; 21(1):153. PubMed ID: 31888717
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations.
    Lopez-Knowles E; Pearson A; Schuster G; Gellert P; Ribas R; Yeo B; Cutts R; Buus R; Garcia-Murillas I; Haynes B; Martin LA; Smith I; Turner N; Dowsett M
    Br J Cancer; 2019 Jan; 120(2):247-255. PubMed ID: 30563991
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. The Dilemma of HER2 Double-equivocal breast Carcinomas: Genomic Profiling and Implications for treatment.
    Marchiò C; Dell'Orto P; Annaratone L; Geyer FC; Venesio T; Berrino E; Verdun di Cantogno L; Garofoli A; Rangel N; Casorzo L; dell'Aglio C; Gugliotta P; Trisolini E; Beano A; Pietribiasi F; Orlassino R; Cassoni P; Pich A; Montemurro F; Mottolese M; Vincent-Salomon A; Penault-Llorca F; Medico E; Ng CKY; Viale G; Sapino A
    Am J Surg Pathol; 2018 Sep; 42(9):1190-1200. PubMed ID: 29975246
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Mutational Profile of Metastatic breast cancers: A Retrospective Analysis.
    Lefebvre C; Bachelot T; Filleron T; Pedrero M; Campone M; Soria JC; Massard C; Lévy C; Arnedos M; Lacroix-Triki M; Garrabey J; Boursin Y; Deloger M; Fu Y; Commo F; Scott V; Lacroix L; Dieci MV; Kamal M; Diéras V; Gonçalves A; Ferrerro JM; Romieu G; Vanlemmens L; Mouret Reynier MA; Théry JC; Le Du F; Guiu S; Dalenc F; Clapisson G; Bonnefoi H; Jimenez M; Le Tourneau C; André F
    PLoS Med; 2016 Dec; 13(12):e1002201. PubMed ID: 28027327
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Cambogin Induces Caspase-Independent Apoptosis through the ROS/JNK Pathway and Epigenetic Regulation in breast cancer Cells.
    Shen K; Xie J; Wang H; Zhang H; Yu M; Lu F; Tan H; Xu H
    Mol Cancer Ther; 2015 Jul; 14(7):1738-49. PubMed ID: 25976678
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. The landscape of candidate driver genes differs between male and female breast cancer.
    Johansson I; Ringnér M; Hedenfalk I
    PLoS One; 2013; 8(10):e78299. PubMed ID: 24194916
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Whole-genome analysis informs breast cancer response to aromatase inhibition.
    Ellis MJ; Ding L; Shen D; Luo J; Suman VJ; Wallis JW; Van Tine BA; Hoog J; Goiffon RJ; Goldstein TC; Ng S; Lin L; Crowder R; Snider J; Ballman K; Weber J; Chen K; Koboldt DC; Kandoth C; Schierding WS; McMichael JF; Miller CA; Lu C; Harris CC; McLellan MD; Wendl MC; DeSchryver K; Allred DC; Esserman L; Unzeitig G; Margenthaler J; Babiera GV; Marcom PK; Guenther JM; Leitch M; Hunt K; Olson J; Tao Y; Maher CA; Fulton LL; Fulton RS; Harrison M; Oberkfell B; Du F; Demeter R; Vickery TL; Elhammali A; Piwnica-Worms H; McDonald S; Watson M; Dooling DJ; Ota D; Chang LW; Bose R; Ley TJ; Piwnica-Worms D; Stuart JM; Wilson RK; Mardis ER
    Nature; 2012 Jun; 486(7403):353-60. PubMed ID: 22722193
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Reduced metastasis-suppressor gene mRNA-expression in breast cancer brain metastases.
    Stark AM; Tongers K; Maass N; Mehdorn HM; Held-Feindt J
    J Cancer Res Clin Oncol; 2005 Mar; 131(3):191-8. PubMed ID: 15592684
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway.
    Lafarge S; Sylvain V; Ferrara M; Bignon YJ
    Oncogene; 2001 Oct; 20(45):6597-606. PubMed ID: 11641785
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.